Navigation Links
Spherix Announces Positive Phase 2 Study Results
Date:6/24/2009

Preliminary Data Demonstrates Reduction of HbA1c Levels With Doses an Order of Magnitude Lower than the Dose Used in the Current Phase 3 Trial.

BETHESDA, Md., June 24 /PRNewswire-FirstCall/ -- Spherix Incorporated (Nasdaq CM: SPEX), an innovator in biotechnology for diabetes therapy, and a provider of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies, today announced positive preliminary results from a Phase 2 clinical trial of its novel compound, Naturlose(R) (D-tagatose), in the treatment and management of Type 2 diabetes. The Phase 2 trial is expected to be completed in early 2010.

In the ongoing single-blind study designed to establish the minimum dose of Naturlose capable of causing a beneficial effect, Naturlose is administered orally with meals, three times daily (TID) at three different doses: 2.5, 5.0, and 7.5 g. The comparator is the 2.5 g dose. The primary endpoint for the study is reduction in HbA1c after 6 months on the drug. After 6 months on drug, the patients in the 7.5 g group experienced an average reduction of 0.3% in HbA1c from the HbA1c of the 2.5 g group. At that same 6-month point, the 5.0 g group averaged a reduction in HbA1c of 0.05% from the 2.5 g group. Naturlose appears to begin showing an effect on HbA1c within the range of doses selected for this minimum-dose study. The ongoing Phase 3 double-blinded study of efficacy is being conducted at a 15 g dose (TID), and is powered to detect a 0.5% reduction in HbA1c.

Over the course of the Phase 2 trial, Naturlose also decreased the average serum triglycerides of the patients by -59 mg/dl by the end of the first month on therapy, a decrease from baseline that remained at -41 mg/dl by the end of the 6 months of the trial. Naturlose also decreased serum LDL by an average -13 mg/dl by the end of the first month on therapy, while serum HDL was essentially unchanged (+0.9 mg/d
'/>"/>

SOURCE Spherix Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Spherix Reports First Quarter 2009 Earnings
2. Spherix Elects New Independent Director, and Elects Chairman of the Board
3. Spherix Postpones 2009 Annual Shareholders Meeting to Share Interim Diabetes Clinical Trial Data
4. Spherix Expands Phase 3 Naturlose Diabetes Trial Outside of the U.S.
5. Spherix D-tagatose to be Supplied by Inalco SpA
6. Growth Achieved in Spherixs Health Sciences Consulting Business
7. Spherix Reports Second Quarter Earnings
8. Covance Announces Integrated Radiolabeled Clinical Pharmacology Studies
9. GeoVax Labs, Inc. Announces Results of 2009 Annual Shareholders Meeting
10. CoAxia, Inc. Announces $21.5M Series D Financing
11. Families of Spinal Muscular Atrophy Announces Latest Developments on Three SMA Drug Discovery Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... analysis of Centers for Medicare and Medicaid Services, (CMS) ... percent of seniors chose lower-cost preferred pharmacy plans that ... The findings were released by Drug Channels . ... of Medicare Part D," said Pharmaceutical Care Management Association ...
(Date:1/23/2015)... DUBLIN , Jan. 23, 2015  Immune Therapeutics, Inc. ... Biotechnology, Inc. for the compounding, packaging and distributing of its ... the United States . ... of compounding naltrexone tablets in various strengths for individual patients ...
(Date:1/23/2015)... 23, 2015  Now available for sale, The Armor1 Ankle ... prevents ankle sprains by cushioning the ankle from an ... around the outside of any shoe type and allows ... still offering protection against sprains. With customers in physical ...
Breaking Medicine Technology:New Analysis: 81 Percent of Medicare Part D Seniors Choose "Preferred Pharmacy" Plans in 2015 2Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 2Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 3Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 4The Armor1 Ankle Roll Guard is the New Breakthrough Solution for Ankle Sprain Prevention! 2
... 2011 /PRNewswire-Asia-FirstCall/ -- Mindray Medical International Limited (NYSE: ... of medical devices worldwide, announced today an agreement to ... Technical Development Co. Ltd. The terms of the transaction ... Mindray,s financial statements. Founded in 2004 and ...
... Nev., Feb. 28, 2011 PDL ... financial results for the fourth quarter and full year ended ... were $345.0 million, compared to $318.2 million in 2009.  Excluding ... royalty revenues for 2010 increased 30 percent over 2009.  For ...
Cached Medicine Technology:Mindray Medical to Acquire a Controlling Stake in Shenke Medical 2Mindray Medical to Acquire a Controlling Stake in Shenke Medical 3Mindray Medical to Acquire a Controlling Stake in Shenke Medical 4PDL BioPharma Announces Fourth Quarter and Full Year 2010 Financial Results 2PDL BioPharma Announces Fourth Quarter and Full Year 2010 Financial Results 3PDL BioPharma Announces Fourth Quarter and Full Year 2010 Financial Results 4PDL BioPharma Announces Fourth Quarter and Full Year 2010 Financial Results 5PDL BioPharma Announces Fourth Quarter and Full Year 2010 Financial Results 6PDL BioPharma Announces Fourth Quarter and Full Year 2010 Financial Results 7PDL BioPharma Announces Fourth Quarter and Full Year 2010 Financial Results 8PDL BioPharma Announces Fourth Quarter and Full Year 2010 Financial Results 9PDL BioPharma Announces Fourth Quarter and Full Year 2010 Financial Results 10
(Date:1/22/2015)... Deer Path of Huntley -- a BMA affordable assisted ... 3 p.m. to 4 p.m. on Feb. 13. , The community, ... adults with physical disabilities between the ages of 22 and 64. ... and sweetheart-themed karaoke. , For more information about the event or ...
(Date:1/22/2015)... LunaDress, with its top dressmaking technologies, has ... the business is showing its latest designs of wedding dresses ... to the company’s CEO, all the fresh new products are ... discounts, up to 80% off. All the clothes from LunaDress ...
(Date:1/22/2015)... Gabe’s Chemo Duck Program is pleased to announce the release ... for kids with cancer. The Chemo Duck App, available on iTunes ... enjoyable games to help children of all ages living with cancer ... keep kids entertained, educated and at ease while waiting for clinic ...
(Date:1/22/2015)... 2015 The Incredible Bulk is a revolutionary ... increase lean muscle by up to 30lbs in less than ... of HealthyandFitZone.com’s Stan Stevenson, prompting an investigative review. , “Our ... step-by-step, scientific diet formula that allows the body to pack ...
(Date:1/22/2015)... the premier women’s dress supplier, has recently released its ... of AngelWeddingDress.com to find more details. , Many ... a bridal party. AngelWeddingDress offers a variety of gorgeous ... wedding dresses are specially designed for 2015. , AngelWeddingDress ...
Breaking Medicine News(10 mins):Health News:Deer Path of Huntley Affordable Assisted Living to Host Valentine's Day Happy Hour 2Health News:LunaDress Shows The Latest Styles Of Wedding Dresses In 2015 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 3Health News:The Incredible Bulk: Review Examining Ben Pakulski’s Brand New Bulking Muscle Building Diet Program Released 2Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2
... Breast cancer patients treated with intensity modulated radiation therapy ... a lower incidence of acute or chronic toxicities, according ... ( PRO ), the official clinical practice journal of ... constantly conducting studies to determine the most effective breast ...
... By Alan Mozes HealthDay Reporter , MONDAY, March ... procedures to standard diabetes treatments contends that surgery is more ... finding stems from two years of tracking 60 severely obese ... ages of 30 and 60. One-third of the patients were ...
... on 31 March when the ship and crew reach Lorient, ... across all the world,s major oceans to sample and investigate ... Karsenti in an editorial published today in Molecular Systems ... yet we know very little about the distribution of marine ...
... HealthDay Reporter , MONDAY, March 26 (HealthDay News) -- ... lowered LDL cholesterol levels in patients with high cholesterol ... treatment could help lower levels of "bad" cholesterol for ... the commonly prescribed cholesterol-lowering drugs known as statins. It ...
... (HealthDay News) -- Antibiotics can prolong cystic fibrosis patients, ... in their lungs, a new, small study suggests. ... not prove, that the current standard of aggressive antibiotic ... the best approach. It,s common to use antibiotics ...
... HealthDay Reporter , MONDAY, March 26 (HealthDay News) -- ... that people who eat chocolate regularly are somewhat skinnier than ... don,t prove that chowing down on chocolate will melt off ... for the modest difference in body mass, or it might ...
Cached Medicine News:Health News:IMRT reduces risk of side effects in breast cancer patients 2Health News:Weight-Loss Surgeries May Beat Standard Treatments for Diabetes 2Health News:Weight-Loss Surgeries May Beat Standard Treatments for Diabetes 3Health News:Weight-Loss Surgeries May Beat Standard Treatments for Diabetes 4Health News:TARA OCEANS completes 60,000-mile journey to map marine biodiversity 2Health News:New Injection Might Lower Tough-to-Treat Cholesterol 2Health News:New Injection Might Lower Tough-to-Treat Cholesterol 3Health News:Should Cystic Fibrosis Patients Get So Many Antibiotics? 2Health News:Does Chocolate Help You Stay Slim? 2Health News:Does Chocolate Help You Stay Slim? 3
...
Ascent Primary Knee System with cruciate retaining, posterior stabilized and constrained components...
... tricompartmental total knee prosthesis stems from many ... design and manufacturing technologies have been used ... as well as a favorable pressure distribution ... keep wear to a minimum. The inherent ...
The Natural-Knee Family is a complete range of interchangeable, anatomically-designed implants with over 14 years of proven clinical results....
Medicine Products: